Wang, M <br/><br/>
Bortezomib is synergistic with rituximab and cyclophosphamide in inducing apoptosis of mantle cell lymphoma cells in vitro and in vivo.  [electronic resource] 

 -  Leukemia  Jan 2008 
 - 179-85 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1476-5551 
<br/><br/><label>Standard No.: </label>10.1038/sj.leu.2404959  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antibodies, Monoclonal--administration & dosage<br/>Antibodies, Monoclonal, Murine-Derived<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Apoptosis--drug effects<br/>Blotting, Western<br/>Boronic Acids--administration & dosage<br/>Bortezomib<br/>Caspases--metabolism<br/>Cell Proliferation<br/>Cyclophosphamide--administration & dosage<br/>Drug Synergism<br/>Immunophenotyping<br/>In Vitro Techniques<br/>Lymphoma, Mantle-Cell--drug therapy<br/>Male<br/>Mice<br/>Mice, SCID<br/>Poly(ADP-ribose) Polymerases--metabolism<br/>Pyrazines--administration & dosage<br/>Rituximab<br/>Survival Rate<br/>Transplantation, Heterologous